Edarbyclor Approved for High Blood Pressure
Condition affects about 1 in 3 Americans
TUESDAY, Dec. 20 (HealthDay News) -- Edarbyclor (azilsartan medoxomil and chlorthalidone) has been approved by the U.S. Food and Drug Administration to treat high blood pressure in adults, maker Takeda Pharmaceutical Co. Ltd. said Tuesday in a news release.
The drug combines Edarbi, an angiotensin II receptor blocker, with the diuretic chlorthalidone. The former blocks the actions of a natural hormone, allowing blood vessels to stay relaxed and open. Diuretics increase the flow of urine from the body, which helps lower blood pressure.
In clinical testing, the combination drug lowered blood pressure "significantly more" than either drug taken alone, Takeda said. The most common adverse reactions included dizziness and fatigue.
High blood pressure affects about 75 million Americans, or nearly one in three adults, the Japanese drug maker said. This includes more than half of people aged 60 and older.
The U.S. National Heart Lung and Blood Institute has more about lowering blood pressure.Scott Roberts Related Articles
- FDA Expands Use of Imbruvica for Form of Leukemia
July 28, 2014
- FDA Approves Hard-to-Abuse Narcotic Painkiller
July 24, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright © 2011 HealthDay. All rights reserved.